Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/26/24
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/20/24
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024GlobeNewsWire • 02/13/24
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaGlobeNewsWire • 12/19/23
Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying OpportunitySeeking Alpha • 11/10/23
Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/09/23
Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/23
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 11/01/23
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023GlobeNewsWire • 10/25/23
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® JourneyGlobeNewsWire • 10/16/23
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York CityGlobeNewsWire • 09/27/23
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/09/23
Radcliffe Capital Management, L.P. Acquires Stake in Portage Fintech Acquisition CorpGuruFocus • 07/27/23
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023GlobeNewsWire • 07/24/23